U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H21N4O8P
Molecular Weight 440.3444
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MB-07133

SMILES

NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO[P@]3(=O)OCC[C@H](O3)C4=CC=NC=C4)[C@@H](O)[C@@H]2O

InChI

InChIKey=HOAHIHGOMCBTFW-XCJSNOFESA-N
InChI=1S/C17H21N4O8P/c18-13-3-7-21(17(24)20-13)16-15(23)14(22)12(28-16)9-27-30(25)26-8-4-11(29-30)10-1-5-19-6-2-10/h1-3,5-7,11-12,14-16,22-23H,4,8-9H2,(H2,18,20,24)/t11-,12+,14+,15-,16+,30-/m0/s1

HIDE SMILES / InChI
Cytarabine ocfosfate (commercial name: Starasid) is a prodrug having stearyl group attached to phosphoric acid at 5' position of arabinose moiety of cytosine arabinoside (Ara-C). This drug is given orally. The mode of action is in the inhibition of DNA synthesis after conversion to Ara-CTP as in Ara-C. The drug is metabolized in the liver, producing the intermediate metabolite, C-C3PCA which is converted to Ara-C gradually. This property results in the maintenance of relatively long time the blood Ara-C levels. This was proved to be active clinically against acute leukemia and MDS.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Starasid

Approved Use

cytarabine ocfosfate is used clinically in Japan for the treatment of leukemia or myelodysplastic syndrome.

Launch Date

1992
Primary
Starasid

Approved Use

cytarabine ocfosfate is used clinically in Japan for the treatment of leukemia or myelodysplastic syndrome.

Launch Date

1992
PubMed

PubMed

TitleDatePubMed
[Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma].
1998 Oct
Patents

Sample Use Guides

For adult acute non-lymphatic leukemia: In general, for adults, take 2-6 capsules (100-300mg of the active ingredient anhydride) in 1-3 divided doses a day after meal. For myelodysplastic syndrome: In general, for adults, take 2-4 capsules (100-200mg of the active ingredient anhydride) in 1-3 divided doses a day after meal, for 2 to 3 weeks every day, then discontinue the medication for 2-3 weeks and repeat this schedule. The dosage may be adjusted according to your disease or symptoms.Strictly follow the instructions.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
MB-07133
Common Name English
MB-7133
Common Name English
4-AMINO-1-(5-O-((2R, 4S)-2-OXIDO-4-(4-PYRIDINYL)-1, 3, 2-DIOXAPHOSPHORINAN-2-YL)-.BETA.-D-ARABINOFURANOSYL)-2(1H)-PYRIMIDINONE
Common Name English
2(1H)-PYRIMIDINONE, 4-AMINO-1-(5-O-((2R,4S)-2-OXIDO-4-(4-PYRIDINYL)-1,3,2-DIOXAPHOSPHORINAN-2-YL)-.BETA.-D-ARABINOFURANOSYL)-
Common Name English
MB 07133 [WHO-DD]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/07/477
Created by admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
FDA ORPHAN DRUG 228106
Created by admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
Code System Code Type Description
SMS_ID
100000181833
Created by admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
PRIMARY
CAS
685111-92-6
Created by admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
PRIMARY
FDA UNII
BNL5ERR07R
Created by admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
PRIMARY
EVMPD
SUB195640
Created by admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
PRIMARY
EPA CompTox
DTXSID00988172
Created by admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
PRIMARY
PUBCHEM
76967524
Created by admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
PRIMARY